How can I provide home parenteral nutrition for a patient with severe mast‑cell activation syndrome (MCAS) when no home parenteral nutrition (HPN) providers are available?

When No HPN Providers Are Available for MCAS Patients

You must establish an in-hospital or institutional HPN program with trained personnel to safely provide this life-saving therapy, as HPN cannot be safely administered without proper infrastructure and an interdisciplinary team. 1

Critical Infrastructure Requirements

The 2023 ESPEN guideline makes clear that HPN is not simply a prescription—it requires a comprehensive program with specific components 1:

Essential Team Members Required

• Physicians trained in HPN management
• Specialized nurses for catheter care and patient training
• Dieticians for nutritional formulation
• Pharmacists for admixture preparation
• Home care coordinators (even if initially hospital-based)

The interdisciplinary approach is not optional—it is fundamental to safe HPN delivery 2. Without this team structure, you cannot safely provide HPN.

Stepwise Approach When No HPN Provider Exists

Step 1: Establish Institutional Capacity

If no commercial HPN provider is available in your region, you must:

• Create an in-hospital HPN program using existing hospital resources
• Train nursing staff on central venous access device (CVAD) care and catheter site management 1
• Coordinate with hospital pharmacy to prepare parenteral nutrition admixtures
• Establish protocols for monitoring and managing complications

Step 2: Address MCAS-Specific Considerations

Before initiating HPN in MCAS patients, optimize mast cell stabilization 3, 4:

• Premedicate aggressively with H1 and H2 antihistamines before any catheter procedures
• Consider prophylactic corticosteroids for CVAD placement
• Have epinephrine immediately available during all procedures 5
• Screen for clonal mast cell disorders (baseline serum tryptase, KIT mutation testing) as these patients have higher anaphylaxis risk 3, 4

Step 3: Transition Planning

The goal must be eventual home administration 1:

• Identify who will write HPN orders post-discharge
• Reach goal infusion rate in hospital before considering home transition
• Train patient/caregiver on CVAD care, recognizing MCAS patients may react to catheter materials or flush solutions
• Coordinate with compounding pharmacy that can prepare admixtures

Critical Pitfalls in MCAS Patients

MCAS patients are at heightened risk for catheter-related reactions due to hypersensitivity to catheter materials, heparin flushes, or PN components 6, 3. You must:

• Test tolerance to all catheter materials and flush solutions before permanent CVAD placement
• Consider silicone catheters over polyurethane if material sensitivity suspected
• Use preservative-free solutions when possible
• Monitor serum tryptase during initial infusions to detect subclinical mast cell activation 3

When HPN Cannot Be Safely Provided

If you cannot establish the minimum infrastructure (trained team, pharmacy support, monitoring protocols), HPN should not be initiated 1. In this scenario:

• Transfer the patient to a facility with HPN capability
• Maintain hospital-based PN until transfer can be arranged
• If transfer is impossible and the patient has chronic intestinal failure requiring life-saving nutrition, you must build the program—there is no alternative for survival 1

The absence of commercial HPN providers does not eliminate the need for proper infrastructure—it mandates that you create it within your institution using the interdisciplinary model. 1, 2